621 related articles for article (PubMed ID: 16741551)
21. [Treatment of cholestatic liver diseases].
Gatzen M; Pausch J
Med Klin (Munich); 2002 Mar; 97(3):152-9. PubMed ID: 11957790
[TBL] [Abstract][Full Text] [Related]
22. Pharmacotherapy of cholestatic liver diseases.
Paumgartner G
J Dig Dis; 2010 Jun; 11(3):119-25. PubMed ID: 20579215
[TBL] [Abstract][Full Text] [Related]
23. [Medical treatment of chronic cholestasis: ursodeoxycholic acid].
Linares Rodríguez A
Gastroenterol Hepatol; 2000 Feb; 23 Suppl 1():24-38. PubMed ID: 11968340
[No Abstract] [Full Text] [Related]
24. Oxidative stress and apoptosis in fetal rat liver induced by maternal cholestasis. Protective effect of ursodeoxycholic acid.
Perez MJ; Macias RI; Duran C; Monte MJ; Gonzalez-Buitrago JM; Marin JJ
J Hepatol; 2005 Aug; 43(2):324-32. PubMed ID: 15970352
[TBL] [Abstract][Full Text] [Related]
25. [Molecular mechanisms of bile formation and cholestatic diseases].
Poupon R
Bull Acad Natl Med; 2003; 187(7):1261-74; discussion 1274-6. PubMed ID: 15146603
[TBL] [Abstract][Full Text] [Related]
26. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
27. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U
J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767
[TBL] [Abstract][Full Text] [Related]
28. [Bile acids in liver diseases--current indications].
Stiehl A
Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
[TBL] [Abstract][Full Text] [Related]
29. Ursodeoxycholic Acid Ameliorates Intrahepatic Cholestasis Independent of Biliary Bicarbonate Secretion in Vil2
Hatano R; Kawaguchi K; Togashi F; Sugata M; Masuda S; Asano S
Biol Pharm Bull; 2017; 40(1):34-42. PubMed ID: 28049946
[TBL] [Abstract][Full Text] [Related]
30. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans.
Marschall HU; Wagner M; Zollner G; Fickert P; Diczfalusy U; Gumhold J; Silbert D; Fuchsbichler A; Benthin L; Grundström R; Gustafsson U; Sahlin S; Einarsson C; Trauner M
Gastroenterology; 2005 Aug; 129(2):476-85. PubMed ID: 16083704
[TBL] [Abstract][Full Text] [Related]
31. Hepatocellular transport in acquired cholestasis: new insights into functional, regulatory and therapeutic aspects.
Roma MG; Crocenzi FA; Sánchez Pozzi EA
Clin Sci (Lond); 2008 May; 114(9):567-88. PubMed ID: 18377365
[TBL] [Abstract][Full Text] [Related]
32. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.
Luketic VA; Sanyal AJ
Gastroenterologist; 1994 Mar; 2(1):74-9. PubMed ID: 8055235
[TBL] [Abstract][Full Text] [Related]
33. Primary biliary cirrhosis and bile acids.
Corpechot C
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S13-20. PubMed ID: 23141888
[TBL] [Abstract][Full Text] [Related]
34. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action.
Poupon R
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S3-12. PubMed ID: 23141891
[TBL] [Abstract][Full Text] [Related]
35. Influence of cholestasis on absorption of ursodeoxycholic acid.
Sauer P; Benz C; Rudolph G; Klöters-Plachky P; Stremmel W; Stiehl A
Dig Dis Sci; 1999 Apr; 44(4):817-22. PubMed ID: 10219843
[TBL] [Abstract][Full Text] [Related]
36. [Ursodeoxycholic acid in the treatment of chronic cholestatic liver disease. Documented delay in disease progress inspires hope].
Olsson R
Lakartidningen; 2002 Mar; 99(12):1325-30. PubMed ID: 11998165
[TBL] [Abstract][Full Text] [Related]
37. Progesterone metabolites and bile acids in serum of patients with intrahepatic cholestasis of pregnancy: effect of ursodeoxycholic acid therapy.
Meng LJ; Reyes H; Axelson M; Palma J; Hernandez I; Ribalta J; Sjövall J
Hepatology; 1997 Dec; 26(6):1573-9. PubMed ID: 9398000
[TBL] [Abstract][Full Text] [Related]
38. Long-term response of primary biliary cirrhosis (stage I) to therapy with ursodeoxycholic acid.
Tromm A; May B; Klein CG; Klein R; Fisseler-Eckhoff A; Griga T
Hepatogastroenterology; 2005; 52(63):753-6. PubMed ID: 15966198
[TBL] [Abstract][Full Text] [Related]
39. Pathogenesis of cholestatic liver disease and therapeutic approaches.
Hirschfield GM; Heathcote EJ; Gershwin ME
Gastroenterology; 2010 Nov; 139(5):1481-96. PubMed ID: 20849855
[TBL] [Abstract][Full Text] [Related]
40. Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis.
Razori MV; Maidagan PM; Ciriaci N; Andermatten RB; Barosso IR; Martín PL; Basiglio CL; Sánchez Pozzi EJ; Ruiz ML; Roma MG
Biochem Pharmacol; 2019 Oct; 168():48-56. PubMed ID: 31202734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
